Aurora Cannabis (NYSE:ACB) Given a $13.50 Price Target by Canaccord Genuity Analysts

Aurora Cannabis (NYSE:ACB) has been given a $13.50 price target by Canaccord Genuity in a research report issued to clients and investors on Friday, TipRanks reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity’s price target would suggest a potential upside of 145.23% from the company’s previous close.

A number of other brokerages also recently commented on ACB. Compass Point began coverage on shares of Aurora Cannabis in a research report on Monday, July 8th. They issued a “neutral” rating for the company. Piper Jaffray Companies set a $7.00 target price on shares of Aurora Cannabis and gave the company a “hold” rating in a report on Friday. Zacks Investment Research raised shares of Aurora Cannabis from a “sell” rating to a “hold” rating in a report on Thursday. LADENBURG THALM/SH SH started coverage on shares of Aurora Cannabis in a report on Wednesday, July 17th. They issued a “buy” rating and a $9.00 target price for the company. Finally, ValuEngine raised shares of Aurora Cannabis from a “hold” rating to a “buy” rating in a report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company’s stock. Aurora Cannabis presently has a consensus rating of “Hold” and a consensus price target of $8.48.

NYSE:ACB traded down $0.45 during mid-day trading on Friday, reaching $5.51. The stock had a trading volume of 29,749,462 shares, compared to its average volume of 12,021,981. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.98 and a current ratio of 1.52. The firm has a market capitalization of $6.01 billion, a price-to-earnings ratio of -25.02 and a beta of 2.47. Aurora Cannabis has a twelve month low of $4.58 and a twelve month high of $12.52. The business has a 50 day simple moving average of $6.06 and a 200 day simple moving average of $7.66.

A number of institutional investors have recently modified their holdings of the business. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its holdings in Aurora Cannabis by 247.1% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 285,802 shares of the company’s stock valued at $2,244,000 after buying an additional 203,468 shares in the last quarter. Stonehage Fleming Financial Services Holdings Ltd purchased a new position in Aurora Cannabis in the second quarter valued at about $54,000. Toronto Dominion Bank increased its holdings in Aurora Cannabis by 13.1% in the second quarter. Toronto Dominion Bank now owns 656,035 shares of the company’s stock valued at $5,139,000 after buying an additional 75,857 shares in the last quarter. Atria Investments LLC purchased a new position in Aurora Cannabis in the second quarter valued at about $587,000. Finally, RFG Advisory LLC increased its holdings in Aurora Cannabis by 25.4% in the second quarter. RFG Advisory LLC now owns 21,395 shares of the company’s stock valued at $169,000 after buying an additional 4,338 shares in the last quarter. 8.88% of the stock is owned by institutional investors.

About Aurora Cannabis

Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

Read More: The role of implied volatility with call option volume

Analyst Recommendations for Aurora Cannabis (NYSE:ACB)

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.